posaconazole
Selected indexed studies
- Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. (Lancet, 2021) [PMID:33549194]
- Posaconazole. (Drugs, 2005) [PMID:16033292]
- Posaconazole. (Drugs Today (Barc), 2005) [PMID:16110346]
_Worker-drafted node — pending editorial review._
Connections
posaconazole is a side effect of
Sources
- Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. (2021) pubmed
- Posaconazole. (2005) pubmed
- Posaconazole. (2005) pubmed
- Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. (2007) pubmed
- Posaconazole in immunocompromised pediatric patients. (2018) pubmed
- Approaches for posaconazole therapeutic drug monitoring and their clinical benefits. (2024) pubmed
- Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments. (2017) pubmed
- Pharmacokinetics and Pharmacodynamics of Posaconazole. (2020) pubmed
- Posaconazole effectiveness in rare invasive fungal infections: A systematic literature review. (2025) pubmed
- Safety of posaconazole. (2013) pubmed